Targeting the cancer mutanome of breast cancer

A metastatic hormone receptor–positive breast cancer, usually resistant to immunotherapy, is successfully treated with tumor-infiltrating lymphocytes enriched for neoantigen reactivity, underscoring the broad potential of this immunotherapeutic approach.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature medicine 2018-06, Vol.24 (6), p.703-704
1. Verfasser:	Radvanyi, Laszlo G.
Format:	Artikel
Sprache:	eng
Schlagworte:	631/250/251 631/67 Antigens Biomedical and Life Sciences Biomedicine Breast cancer Cancer Cancer metastasis Cancer Research Cancer treatment Care and treatment DNA Gene mutation Genetic aspects Immune system Immunotherapy Infectious Diseases Lymphocytes Major histocompatibility complex Metabolic Diseases Metastases Molecular Medicine Neoantigens Neurosciences News & Views news-and-views Peptides RNA RNA sequencing Tumor antigens Tumor-infiltrating lymphocytes Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	A metastatic hormone receptor–positive breast cancer, usually resistant to immunotherapy, is successfully treated with tumor-infiltrating lymphocytes enriched for neoantigen reactivity, underscoring the broad potential of this immunotherapeutic approach.
ISSN:	1078-8956 1546-170X
DOI:	10.1038/s41591-018-0065-z